Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy and Systemic Therapy in Oligometastatic UTUC
NCT06652022Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jan 2022
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Randomised, open-label trial in upper tract urothelial carcinoma (UTUC) (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Progression-Free Survival at 5 years. Started Jan 2022; status: recruiting.
02
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT06652022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06652022.